Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Registrational study of trem-cel plus Mylotarg

Next Previous
X
Search
Trial Profile

Registrational study of trem-cel plus Mylotarg

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gemtuzumab ozogamicin (Primary) ; Tremtelectogene empogeditemcel (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 22 Dec 2024 New trial record
    • 09 Dec 2024 According to a Vor Biopharma media release, the Company had the opportunity to interact with the FDA and Company has received supportive feedback from the FDA regarding trial design. There was agreement with the trem-cel + Mylotarg registrational clinical trial design with respect to study population, control arm, primary endpoint, stratification factors, and statistical design. The Company agreed to provide further updates to the FDA alongside submission of the full clinical trial protocol.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top